ADVERTISEMENT

Clinical Summary

Type 2 diabetes: sodium-glucose cotransporter-2 inhibitor cardiovascular benefits increase with BMI

Miriam Tucker   |   12 October 2022

Takeaway

  • Real-world data confirm sodium-glucose cotransporter-2 inhibitor (SGLT2i) use is associated with decreased cardiovascular outcomes and mortality vs dipeptidyl peptidase-4 inhibitors (DPP-4is).
  • Greater benefit is seen in those with obesity/severe obesity.

Why this matters

  • Obesity may alter efficacy of drugs with lipophilic properties.
  • SGLT2is are liposoluble.
  • No previous study has...

          

November Challenge

Ends in 9h
left
right

Topic Challenges

left
right